Immune microenvironment and immunotherapy of meningioma
Meningioma is the most common type of primary intracranial tumor and includes grade I,II and III by the world health organization(WHO)classification in 2021.With the increase of grade,the higher the recurrence rate of tumor,the worse the prognosis.Surgery is the main treatment,and radiotherapy is used for residual or recurrent tumors.However,some patients often lost the opportunity of surgery and radiotherapy who recurred after multiple surgeries or radiotherapy.Medical treatment is limited.Therefore,effective treatment is an urgent problem to be solved.In recent years,immunotherapy has achieved good efficacy in a variety of malignant tumors.Meningioma also harbors abundant immune microenvironment basing on the large of evidence of genome and infiltrated immune cells of meningioma,immunotherapy may be a choice for the treatment of recurrent or refractory meningioma.This article mainly reviews the components of the immune microenvironment in meningioma and the progress of immunotherapy,and summarizes the expression and application of immune checkpoint proteins in the meningioma in the past years,aiming to find out effective immune targets for clinical transformation and bring new hope for meningioma patients.
NETL
NSTL
万方数据
